Research Study of Visilizumab for Treatment of Glucocorticoid- Refractory Graft Versus Host Disease

Fred Hutchinson Cancer Center80 enrolled

Overview

The purpose of this phase II study is to evaluate an investigational monoclonal antibody for the treatment of glucocorticoid-refractory Graft Versus Host Disease (GVHD). Patients diagnosed with GVHD who have not responded satisfactorily to, or are intolerant of, treatment with standard agents will be considered for entry. Patients will be allowed to continue on their other immunosuppressive drugs at stable doses during the trial. The research is being conducted at up to 20 clinical research sites in the US.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Graft-vs-Host Disease

Interventions

VisilizumabDRUG

Eligibility

Sex: ALLMin age: 0 Years

Medical Language ↔ Plain English

* Grade II to IV GVHD * Clinical findings: skin thickening, joint contraction, oral ulceration, diarrhea. * History of allogeneic hematopoietic cell transplant (HCT). * Patients must have failed to respond or clearly progress to previous therapy on or before day +100 posttransplant. * Patients must have adequate renal, hepatic, cardiac function and hematologic values

Locations (17)

City of Hope National Medical Center

Duarte, California, United States

Stanford University Medical Center

Stanford, California, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.